A state of acquired IL-10 deficiency in 0.4% of Danish blood donors

Cytokine

Volumn 51, Issue 3, 2010, Pages 286-293

  de Lemos Rieper, Carina ^a,b   Galle, Pia ^b   Pedersen, Bente Klarlund ^b   Hansen, Morten Bagge ^a  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Autoimmunity; Cytokines; Immune deficiency; Immunological tolerance

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 19; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 24; INTERLEUKIN 26; INTERLEUKIN 28A; INTERLEUKIN 28B; INTERLEUKIN 29; UNCLASSIFIED DRUG; ANTIBODY; AUTACOID; IMMUNOGLOBULIN RECEPTOR;

AFFINITY CHROMATOGRAPHY; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; BLOOD DONOR; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENMARK; HUMAN; HUMAN CELL; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; RADIOIMMUNOASSAY; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BLOOD; DEFICIENCY; IMMUNOLOGY; METABOLISM;

ANTIBODIES; ANTIBODY AFFINITY; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; BLOOD DONORS; C-REACTIVE PROTEIN; DENMARK; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; RECEPTORS, IMMUNOLOGIC;

EID: 77955278879     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.06.009     Document Type: Article

References (34)

1. Couper K.N., Blount D.G., Riley E.M. IL-10: the master regulator of immunity to infection. J. Immunol. 2008, 180:5771-5777.
2. Moore K.W., de Waal M.R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19:683-765.
3. Murray P.J. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr. Opin. Pharmacol. 2006, 6:379-386.
4. Kuhn R., Lohler J., Rennick D., Rajewsky K., Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
5. Chang W.L., Baumgarth N., Yu D., Barry P.A. Human cytomegalovirus-encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality. J. Virol. 2004, 78:8720-8731.
6. Liu Y., de Waal M.R., Briere F., et al. The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. J. Immunol. 1997, 158:604-613.
7. Spencer J.V., Lockridge K.M., Barry P.A., et al. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J. Virol. 2002, 76:1285-1292.
8. Zdanov A. Structural features of the interleukin-10 family of cytokines. Curr. Pharm. Des 2004, 10:3873-3884.
9. Erikstrup C., Kallestrup P., Zinyama-Gutsire R.B., et al. Reduced mortality and CD4 cell loss among carriers of the interleukin-10 -1082G allele in a Zimbabwean cohort of HIV-1-infected adults. AIDS 2007, 21:2283-2291.
10. Svenson M., Hansen M.B., Ross C., et al. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 1998, 91:2054-2061.
11. Hansen M.B., Svenson M., Abell K., et al. Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors. Eur. J. Immunol. 1995, 25:348-354.
12. Svenson M., Hansen M.B., Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J. Clin. Invest 1993, 92:2533-2539.
13. Menetrier-Caux C., Briere F., Jouvenne P., et al. Identification of human IgG autoantibodies specific for IL-10. Clin. Exp. Immunol. 1996, 104:173-179.
14. de Lemos R.C., Galle P., Svenson M., Pedersen B.K., Hansen M.B. Preparation and validation of radio iodinated recombinant human IL-10 for the measurement of natural human antibodies against IL-10. J. Immunol. Methods 2009, 350:46-53.
15. Tanner J.E., Diaz-Mitoma F., Rooney C.M., Alfieri C. Anti-interleukin-10 antibodies in patients with chronic active Epstein-Barr virus infection. J. Infect. Dis. 1997, 176:1454-1461.
16. Svenson M., Poulsen L.K., Fomsgaard A., Bendtzen K. IgG autoantibodies against interleukin 1 alpha in sera of normal individuals. Scand. J. Immunol. 1989, 29:489-492.
17. de Lemos R.C., Galle P., Hansen M.B. Characterization and potential clinical applications of autoantibodies against cytokines. Cytokine Growth Factor Rev. 2009.
18. Galle P., Svenson M., Bendtzen K., Hansen M.B. High levels of neutralizing IL-6 autoantibodies in 0. 1% of apparently healthy blood donors. Eur. J. Immunol. 2004, 34:3267-3275.
19. Fudala R., Krupa A., Stankowska D., Allen T.C., Kurdowska A.K. Anti-interleukin-8 autoantibody:interleukin-8 immune complexes in acute lung injury/acute respiratory distress syndrome. Clin. Sci. (Lond) 2008, 114:403-412.
20. Meager A., Visvalingam K., Peterson P., et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS. Med. 2006, 3:e289.
21. Krupa A., Kato H., Matthay M.A., Kurdowska A.K. Proinflammatory activity of anti-IL-8 autoantibody:IL-8 complexes in alveolar edema fluid from patients with acute lung injury. Am. J. Physiol Lung Cell Mol. Physiol 2004, 286:L1105-L1113.
22. Bonfield T.L., Russell D., Burgess S., et al. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am. J. Respir. Cell Mol. Biol. 2002, 27:481-486.
23. Bendtzen K., Hansen M.B., Ross C., Svenson M. Detection of autoantibodies to cytokines. Mol. Biotechnol. 2000, 14:251-261.
24. Opal S.M., DePalo V.A. Anti-inflammatory cytokines. Chest 2000, 117:1162-1172.
25. Kearney J.F. Formation of autoantibodies, including anti-cytokine antibodies, is a hallmark of the immune response of early B cells. J. Interferon Res. 1994, 14:151-152.
26. Strobel P., Murumagi A., Klein R., et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J. Pathol. 2007, 211:563-571.
27. Meager A., Wadhwa M., Dilger P., et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin. Exp. Immunol. 2003, 132:128-136.
28. Zhang W., Liu J.L., Meager A., Newsom-Davis J., Willcox N. Autoantibodies to IL-12 in myasthenia gravis patients with thymoma; effects on the IFN-gamma responses of healthy CD4+ T cells. J. Neuroimmunol. 2003, 139:102-108.
29. Shiono H., Wong Y.L., Matthews I., et al. Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int. Immunol. 2003, 15:903-913.
30. Antonelli G., Currenti M., Turriziani O., Dianzani F. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J. Infect. Dis. 1991, 163:882-885.
31. Antonelli G., Simeoni E., Currenti M., et al. Interferon antibodies in patients with infectious diseases anti-interferon antibodies. Biotherapy 1997, 10:7-14.
32. von Wussow P., Freund M., Dahle S., et al. Immunogenicity of different types of interferons in the treatment of hairy-cell leukemia. N. Engl. J. Med. 1988, 319:1226-1227.
33. Hansen M.B., Ross C., Berg K. A sensitive antiviral neutralization bioassay for measuring antibodies to interferons. J. Immunol. Methods 1990, 127:241-248.
34. Llorente L., Richaud-Patin Y., Garcia-Padilla C., et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 2000, 43:1790-1800.